Skip to content

Soluble Corn Fiber on BMD in Pre-pubertal Boys and Girls (PREBONE-Kids)

Effects of Soluble Corn Fiber on BMC, BMD and Bone Biomarkers of Pre-pubertal Boys and Girls : a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03864172
Acronym
PREBONE-Kids
Enrollment
243
Registered
2019-03-06
Start date
2017-08-02
Completion date
2019-08-01
Last updated
2019-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Health

Brief summary

The aim of this study is to investigate the effects of soluble corn fiber (SCF) on bone mineral content (BMC) and bone mineral density (BMD) in pre-pubertal boys and girls. The hypothesis to be tested is: SCF will lead to greater increase of BMD, as measured with densitometry in both low calcium as well as high calcium intakes compared to placebo.

Detailed description

Main objective To investigate the effects of soluble corn fiber (SCF) supplementation on bone mineral content (BMC) and bone mineral density (BMD) in pre-pubertal boys and girls. Secondary objectives The secondary objectives are: To investigate changes in bone formation and bone resorption markers in response to soluble corn fiber supplementation in the diet of prepubertal boys and girls consuming adequate calcium intake vs placebo To investigate changes in body composition in response to soluble corn fiber supplementation in the diet of prepubertal boys and girls consuming adequate calcium intake vs placebo Hypothesis Soluble corn fiber would lead to improved BMC and BMD accrual in pre-pubertal children compared to placebo. Study design The proposed study is a double blind, randomized, single center, parallel design trial Duration of study The duration of the study intervention would be 12 months

Interventions

DIETARY_SUPPLEMENTUsual intake + placebo fruit juice

Participants will consume 200 mls of placebo fruit flavoured juice

DIETARY_SUPPLEMENTUsual intake+SCF fruit juice

Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)

DIETARY_SUPPLEMENTAdequate calcium + placebo fruit juice

Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI

DIETARY_SUPPLEMENTAdequate calcium+ SCF fruit juice

Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI

Sponsors

Tate & Lyle
CollaboratorINDUSTRY
IMU University, Malaysia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Double blind study

Intervention model description

Randomised controlled Trial

Eligibility

Sex/Gender
ALL
Age
9 Years to 11 Years
Healthy volunteers
Yes

Inclusion criteria

* Screened to be generally healthy as determined by standard medical assessment on physical and mental health * Tanner stage 2 based on breast development for girls, and pubic hair in boys. Girls will have to be premenarcheal * Having obtained his/her informed consent and parents or legal guardians consent

Exclusion criteria

* History of serious medical conditions such as intestinal or severe metabolic diseases, disorders such as diabetes, renal, hepatic or pancreatic diseases, disorders, ulcer, hyperthyroidism, malignance, chronic malnutrition, anaemia * History or on therapy with medication known to interfere with bone metabolism such as steroids, hormones, diuretics, cortisone or anti-seizure medication * Taking regularly any nutritional supplements and unwilling to stop for the study

Design outcomes

Primary

MeasureTime frameDescription
Bone mineral density ( BMD)12 monthsBMD at total body and lumbar spine L1-L4
Bone mineral content (BMC)12 monthsBMC at total body and lumbar spine L1-L4

Secondary

MeasureTime frameDescription
Bone biomarkers12 monthsSerum CTX1, P1NP, osteocalcin & BAP

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026